Healthcare & Life Sciences
Metabolys
France
acquiredacquired
acquired
Stage
1
Investors
About
Metabolys developed a proprietary, patent-protected peptide drug ('PATAS') that reverses insulin resistance to treat type 2 diabetes and related metabolic disorders by improving lipid biosynthesis in adipocytes, thereby restoring glycemic control and reducing cardiovascular and renal risks.
Explore Metabolys's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.